Upgrade to SI Premium - Free Trial

Prime Medicine (PRME)

3.21 +0.03 (0.94%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/30/26)

Latest Headlines

Prime Drink Group Provides Bi-Weekly MCTO Status Report September 10, 2026 5:30 PM - Globe NewsWire Prime Drink Group closes first tranche of private placement at $1.35M September 10, 2026 7:30 AM - StreetInsider Prime Drink Group Announces First Closing of Private Placement September 10, 2026 7:30 AM - Globe NewsWire Prime Medicine to Participate in Upcoming Investor Conferences September 3, 2026 8:00 AM - StreetInsider Prime Drink Group Provides Bi-Weekly MCTO Status Report August 27, 2026 5:30 PM - Globe NewsWire Prime Drink Group signs LOI with Geloso for beverage brand expansion August 27, 2026 7:31 AM - StreetInsider Prime Drink Group Enters Into Strategic Partnership With Groupe Geloso to Accelerate the Expansion of Beach Day Every Day Across the Rest of Canada, the United States and Europe August 27, 2026 7:31 AM - Globe NewsWire BMO Capital Starts Prime Medicine (PRME) at Outperform August 18, 2026 4:13 PM - StreetInsider Prime Drink Group Provides Bi-Weekly MCTO Status Report August 14, 2026 4:00 PM - Globe NewsWire Prime Medicine, Inc. (PRME) Tops Q2 EPS by 12c August 6, 2026 8:33 AM - StreetInsider Form 10-Q Prime Medicine, Inc. For: Jun 30 August 6, 2026 8:04 AM - SEC Filing Form 8-K Prime Medicine, Inc. For: Aug 06 August 6, 2026 8:02 AM - SEC Filing Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates August 6, 2026 8:00 AM - StreetInsider Prime Drink Group extends private placement, misses filing deadline July 30, 2026 5:30 PM - StreetInsider Prime Drink Group Extends Private Placement and Announces Delay in Filing Annual Financial Statements July 30, 2026 5:30 PM - Globe NewsWire Prime Medicine gets FDA clearance for Wilson disease gene therapy trial July 23, 2026 4:05 PM - StreetInsider Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease July 23, 2026 4:05 PM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME) July 10, 2026 6:52 AM - StreetInsider TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential' July 8, 2026 12:30 PM - StreetInsider BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff July 8, 2026 11:32 AM - StreetInsider Form 8-K Prime Medicine, Inc. For: Jul 06 July 8, 2026 8:02 AM - SEC Filing Prime Medicine wins arbitration against Beam Therapeutics over PM647 July 8, 2026 8:00 AM - StreetInsider Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics July 8, 2026 8:00 AM - StreetInsider H.C. Wainwright Upgrades Prime Medicine (PRME) to Buy June 29, 2026 6:03 AM - StreetInsider FDA grants RMAT designation to Prime Medicine's CGD therapy PM359 June 22, 2026 8:02 AM - StreetInsider Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) June 22, 2026 8:00 AM - StreetInsider Prime Medicine (PRME) Reiterated at Market Outperform by Citizens as Trial Announced June 22, 2026 4:16 AM - StreetInsider Prime Medicine gets New Zealand clearance for Wilson disease gene therapy June 18, 2026 8:03 AM - StreetInsider Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease June 18, 2026 8:00 AM - StreetInsider Full Article List